Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H25NO3.ClH |
| Molecular Weight | 363.878 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=ZCEHOOLYWQBGQO-UHFFFAOYSA-N
InChI=1S/C20H25NO3.ClH/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5-14,23H,3-4,15-16H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H25NO3 |
| Molecular Weight | 327.4174 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Benactyzine, an anticholinergic drug, had been used as an antidepressant in the treatment of depression and associated anxiety. It is no longer used in medicine due to its ineffectiveness but is widely used in scientific research. Benactyzine is a muscarinic antagonist which also inhibits the nicotinic acetylcholine receptor.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 |
|||
Target ID: Nicotinic acetylcholine receptor |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Deprol Approved Usetreatment of depression |
|||
| Primary | Anxiolit plus Approved UseAnxiety states of tension and excitement change of symptoms discomfort of the gastrointestinal tract, the cardiovascular system and the urinary tract due to psychological causes (psychovegetative complaints) |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1300 mg single, oral Overdose |
unknown |
Disc. AE: Psychosis... AEs leading to discontinuation/dose reduction: Psychosis Sources: |
200 mg single, oral Overdose |
healthy |
Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium (severe) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Psychosis | Disc. AE | 1300 mg single, oral Overdose |
unknown |
| Delirium | severe Disc. AE |
200 mg single, oral Overdose |
healthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Tolerance of prostate biopsy with use of local anesthesia and benzodiazepines: a randomized, prospective study]. | 2010-01 |
|
| Paraoxon attenuates vascular smooth muscle contraction through inhibiting Ca2+ influx in the rabbit thoracic aorta. | 2010 |
|
| Sexual function in adult male rats after prenatal modulation of the cholinergic system. | 2009-06 |
|
| Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. | 2009 |
|
| Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. | 2008-10-15 |
|
| The present approaches to the development of prophylactic and therapeutic antidotes against nerve agents. | 2008-06 |
|
| Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. | 2008-06 |
|
| [The sexual function of mature rat males after prenatal modulation of cholinergic system]. | 2008-05 |
|
| Role of the cholinergic mechanisms of the ventrolateral preoptic area of the hypothalamus in regulating the state of sleep and waking in pigeons. | 2008-03 |
|
| Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen. | 2008-02-15 |
|
| Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. | 2008-02 |
|
| Protective effect of reversible cholinesterase inhibitors (tacrine, pyridostigmine) and eqbuche against VX poisoning and brain acetylcholinesterase inhibition in rats. | 2008 |
|
| Therapeutic and neuroprotective efficacy of pharmacological pretreatment and antidotal treatment of acute tabun or soman poisoning with the emphasis on pretreatment drug PANPAL. | 2006-12 |
|
| The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice. | 2006-01 |
|
| Role of cholinergic structures in individual resistance of rat circulatory system to posthemorrhagic hypoxia. | 2005-08 |
|
| Protection and inflammatory markers following exposure of guinea pigs to sarin vapour: comparative efficacy of three oximes. | 2004-11-24 |
|
| Acute experimental tabun-induced intoxication and its therapy in rats. | 2004-03 |
|
| Therapeutic efficacy of different antidotal mixtures against poisoning with GF-agent in mice. | 2004 |
|
| Anticholinergic drugs--functional antidotes for the treatment of tabun intoxication. | 2004 |
|
| Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. | 2003-09 |
|
| Neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in tabun-poisoned rats. | 2003-03-14 |
|
| Effect of methoxime combined with anticholinergic, anticonvulsant or anti-HCN drugs in tabun-poisoned mice. | 2003 |
|
| A comparison of the neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in soman-poisoned rats. | 2003 |
|
| A comparison of the efficacy of pyridostigmine alone and the combination of pyridostigmine with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice. | 2002-08-15 |
|
| The influence of anticholinergic drug and oxime selection on the effectiveness of antidotal treatment against tabun-induced poisoning in mice. | 2002 |
|
| Effects of advanced candidate anticonvulsants under two rodent models of 'counting'. | 2001-12 |
|
| Effects of selected anticholinergics on acoustic startle response in rats. | 2001-12 |
|
| [Effect of diazepam on antidote therapy of lethal toxic effects of soman in rats]. | 2001-09 |
|
| [Effect of diazepam on the effectiveness of antidote therapy in eliminating the acute lethal effects of soman in mice]. | 2001-08 |
|
| Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase. | 2001-02-01 |
|
| The influence of anticholinergic drug selection on the effectiveness of oximes against soman-induced supralethal poisoning in mice. | 2001 |
|
| [The possible role of presynaptic effects in realizing the protective action of M-cholinolytics in dimethyl dichlorovinyl phosphate poisoning]. | 1991-07-01 |
|
| [Effect of several neuroleptic, adreno-, sympatho- and cholinolytic substances on the development of experimental cerebral edema induced by nicotine]. | 1977-05-01 |
|
| Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. | 1969-03-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:34:34 GMT 2025
by
admin
on
Mon Mar 31 17:34:34 GMT 2025
|
| Record UNII |
26R628272Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB00693MIG
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
26R628272Q
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
m2301
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
66448
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
C78059
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
16339
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
100000084992
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
314518
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID8052774
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
200-324-4
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY | |||
|
57-37-4
Created by
admin on Mon Mar 31 17:34:34 GMT 2025 , Edited by admin on Mon Mar 31 17:34:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |